Follicular lymphoma is characterized by repeated treatment responses and then relapses and researchers will need to generate a growing list of drug choices to keep pace with patients’ needs.
Beth Fand Incollingo
Advertisement
Articles by Beth Fand Incollingo
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
